News

Research and development expenses rose 68.8% year-over-year in Q2 2025, reflecting ongoing clinical trial spending, while revenue remained at zero. Protara ended the quarter with $145.6 million in ...
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI ® in ...
Treatment Arms: Patients in the active treatment arm will receive two 70mg loading doses (Day 1 and Week 8) followed by two 45mg maintenance doses (Week 24 and Week 40). All patients will continue to ...